Background Poisoning is one of the leading causes of admission to the emergency
department and intensive care unit. A large number of epidemiological changes have …

Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared
to vitamin K antagonists (VKAs) for the prevention and treatment of venous …

Historically, the clinical application of extracorporeal treatments (ECTRs), such as
hemodialysis or hemoperfusion, was first intended for poisoned patients. With time, ECTRs …

Background Dabigatran, a direct thrombin inhibitor, is effective for the treatment of venous
thromboembolism and the prevention of stroke and systemic embolism resulting from atrial …

Pharmacologic toxicities are common and range from mild to life‐threatening. The aim of this
study is to review and update the data on the role of renal replacement therapy (RRT) in the …

The worldwide increase in the aging population and the associated increase in the
prevalence of atrial fibrillation and venous thromboembolism as well as the widespread use …

Introduction Direct oral anticoagulants (DOAC) are increasingly used for the prevention and
treatment of thromboembolic events. However, only little evidence is available regarding the …

Introduction: Dabigatran, a direct thrombin inhibitor, is 80% renally eliminated and
demonstrates multi-compartmental pharmacokinetics. Idarucizumab is a monoclonal …

Purpose Current knowledge on managing major bleeding events with available hemostatic
agents, including their combined use with potential reversal agents, in patients taking direct …

The direct-acting oral anticoagulants (DOACs) have been increasingly used over vitamin K
antagonists in recent years because they do not require monitoring and have an immediate …